Use one of the following options to find your doctor at Cabrini
or
Malvern
Brighton

Looking for a physiotherapist or other professional? See Allied Health

Cancer Trials at Cabrini

The Oncology Clinical Trials Program enables patients to access a wide spectrum of newly advanced treatments including immunotherapeutic drugs and targeted therapies for a range of solid and haematological malignancies.

 

Established in 2003 and led by Associate Professor Gary Richardson OAM, the Department aims to provide compassionate, state-of-the-art care for cancer patients and continued advancements in the prevention, diagnosis, treatment and cure of cancer via a combination of research, education and clinical practice.

Phase I

A phase 1 multicenter, dose escalation study of CBT-501 in subjects with select advanced or relapsed/recurrent solid tumors

Protocol Number - CBT-501-01

Download more information >

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers

Protocol Number - CK-301-101

Download more information >

A phase 1, multi-center, open-label, single-arm, dose-escalation, clinical study to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of FN-1501 monotherapy in patients with advanced solid tumors

Protocol Number - ALE17001/FN-1501-UP1

Download more information >

A Phase I, open-label, dose-escalation study of the safety and pharmacokinetics of HMPL-523 in patients with relapsed or refractory hematological malignancies (expansion phase)

Protocol Number - HMPL-523 (2015-523-00AU1)

Download more information >

A Phase 1B/2 Open-label study to evaluate safety, clinical activity, pharmacokinetics and pharmacodynamics of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with advanced malignancies

Protocol Number - B9991004

Download more information >

An Open-Label, Multicenter, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of KN046 in Subjects with Advanced Solid Tumors.

Protocol Number - KN046-AUS-001

Download more information >

A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors (HLX20)

Protocol Number - HLX20-001

Download more information >

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Protocol Number - B9991023

Download more information >

Melanoma

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced Cancers

Protocol Number - CK-301-101

Download more information >

An Open-Label, Multicenter, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of KN046 in Subjects with Advanced Solid Tumors.

Protocol Number - KN046-AUS-001

Download more information >

A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors (HLX20)

Protocol Number - HLX20-001

Download more information >

Lung

A phase 1 multicenter, dose escalation study of CBT-501 in subjects with select advanced or relapsed/recurrent solid tumors

Protocol Number - CBT-501-01

Download more information >

An Open-Label, Multicenter, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of KN046 in Subjects with Advanced Solid Tumors.

Protocol Number - KN046-AUS-001

Download more information >

A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors (HLX20)

Protocol Number - HLX20-001

Download more information >

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Protocol Number - B9991023

Download more information >

Haematological / Blood cancers

A Phase I, open-label, dose-escalation study of the safety and pharmacokinetics of HMPL-523 in patients with relapsed or refractory hematological malignancies (expansion phase)

Protocol Number - HMPL-523 (2015-523-00AU1)

Download more information >

Colorectal

A phase 1 multicenter, dose escalation study of CBT-501 in subjects with select advanced or relapsed/recurrent solid tumors

Protocol Number - CBT-501-01

Download more information >

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colon Cancer (DYNAMIC)

Protocol Number - WEHI-ctDNA-04

Download more information >

An Open-Label, Multicenter, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of KN046 in Subjects with Advanced Solid Tumors.

Protocol Number - KN046-AUS-001

Download more information >

Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Locally Advanced Rectal Cancer: A Multicentre Randomised Study

Protocol Number - WEHI-ctDNA11

Download more information >

A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors (HLX20)

Protocol Number - HLX20-001

Download more information >

Genitourinary

A phase 1 multicenter, dose escalation study of CBT-501 in subjects with select advanced or relapsed/recurrent solid tumors

Protocol Number - CBT-501-01

Download more information >

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency

Protocol Number - CO-338-052

Download more information >

A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

Protocol Number - CA209914

Download more information >

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Protocol Number - CA2099ER

Download more information >

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs.Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Protocol Number - CX-839-008

Download more information >

An Open-Label, Multicenter, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of KN046 in Subjects with Advanced Solid Tumors.

Protocol Number - KN046-AUS-001

Download more information >

A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors (HLX20)

Protocol Number - HLX20-001

Download more information >

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Protocol Number - B9991023

Download more information >

Breast Cancer

Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)

Protocol Number - ONT-380-206

Download more information >

A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer.

Protocol Number - C040016

Download more information >

A randomized, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

Protocol Number - D081CC00006

Download more information >

An Open-Label, Multicenter, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of KN046 in Subjects with Advanced Solid Tumors.

Protocol Number - KN046-AUS-001

Download more information >

A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors (HLX20)

Protocol Number - HLX20-001

Download more information >

Gynaecological

A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128 + MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MPL0128 in Women with Advanced, Recurrent, or Persistent Endometrial Cancer

Protocol Number - C31004

Download more information >

A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Protocol Number - YO39523

Download more information >

A phase 1 multicenter, dose escalation study of CBT-501 in subjects with select advanced or relapsed/recurrent solid tumors

Protocol Number - CBT-501-01

Download more information >

Circulating Tumour DNA as a Marker of Residual Disease and Response to Adjuvant Chemotherapy in Stage I-III Optimally Debulked Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer (EOC)

Protocol Number - WEHI-ctDNA-10

Download more information >

An Open-Label, Multicenter, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of KN046 in Subjects with Advanced Solid Tumors.

Protocol Number - KN046-AUS-001

Download more information >

A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors (HLX20)

Protocol Number - HLX20-001

Download more information >

Gastrointestinal

A phase 1 multicenter, dose escalation study of CBT-501 in subjects with select advanced or relapsed/recurrent solid tumors

Protocol Number - CBT-501-01

Download more information >

An Open-Label, Multicenter, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of KN046 in Subjects with Advanced Solid Tumors.

Protocol Number - KN046-AUS-001

Download more information >

A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors (HLX20)

Protocol Number - HLX20-001

Download more information >

Pancreatic

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

Protocol Number - AM0010-301

Download more information >

A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC).

Protocol Number - CanStem111P

Download more information >

An Open-Label, Multicenter, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of KN046 in Subjects with Advanced Solid Tumors.

Protocol Number - KN046-AUS-001

Download more information >

A Phase 1 Study of HLX20, a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors (HLX20)

Protocol Number - HLX20-001

Download more information >

There are no results to your search.

The keyword you entered is too short. Please use at least three characters.